Executive Team

Dr. Kurt Stoeckli

President and Chief Scientific OfficerDr. Kurt Stoeckli

Dr. Kurt Stoeckli is President and Chief Scientific Officer of Glenmark Pharmaceuticals Ltd., based in Neuchâtel, Switzerland. He oversees global research and early development of innovative products including new biological entities and new chemical entities, with operations in Switzerland, U.S. and India. He also manages both the generics and the branded formulations research. Dr. Stoeckli brings more than 25 years of experience inbiopharmaceutical research and development in the global life sciences industry. Prior to joining Glenmark Pharmaceuticals in 2016, Dr. Stoeckli assumed executive roles at SANOFI, first as global therapeutic area head of immunology and inflammation in Germany, and most recently as Group Vice President for the Global Biotherapeutics Division in Paris. Dr. Stoeckli first joined the industry in 1993 at Novartis in Basel, Switzerland where he held increasingly senior leadership positions and provided global support for all biomedical research activities at the Novartis Lead Discovery Center. An immunologist and chemist by training, he graduated from the University of Basel, ETH Zurich and the Max-Planck-Institute for Neurobiology in Munich where he received his Ph.D. in Molecular Cell Biology. Dr. Stoeckli is a Postdoctoral Fellow & Assistant Professor in the Department of Biochemistry & Biophysics, University of California Medical Center.

President and Chief Medical Officer

Dr. Fred Grossman

President and Chief Medical OfficerDr. Fred Grossman

Dr. Fred Grossman, DO, FAPA is President and Chief Medical Officer of Glenmark Pharmaceuticals Ltd. He oversees global clinical development, pharmacovigilance, medical affairs and clinical operations for innovative product development as well as specialty and generic products. In this role, he furthers Glenmark’s investments in research to generate assets that address unmet medical needs in a variety of therapeutic areas. Dr. Grossman has more than 20 years of international experience directing research and development of potential new medicines for leading pharmaceutical organizations. Before joining Glenmark in 2015, he held global medical leadership positions at Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, and Sunovion. Dr. Grossman is a board-certified physician, completed a fellowship in pharmacology at the National Institutes of Health, has several academic appointments and is the author of numerous scientific publications. He received his medical degree from Hahnemann University in Philadelphia, Pennsylvania.

Prior to joining Glenmark in 2017, he was the President Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla and played a key role in acquisition of various companies in emerging and mature markets for the organization. He is a qualified Chartered Accountant and holds a Bachelor’s degree in Commerce from Mumbai University.

President, North America and Global API Business

Mr. Robert Matsuk

President, North America and Global API BusinessMr. Robert Matsuk

Mr. Robert Matsuk is President of North America at Glenmark Pharmaceuticals Ltd. He has overall responsibility for the company’s generics and branded pharmaceutical business in North America and the global API business at Glenmark. Prior to joining Glenmark in 2014, he was Executive Vice President and Chief Strategy Officer at HighPoint Solutions where he had overall responsibility for the life sciences business. Mr. Matsuk also held other senior leadership positions within the life sciences industry at PricewaterhouseCoopers and Computer Sciences Corporation. He received his Masters in Business Administration from Northwestern University’s J.L. Kellogg Graduate School of Management and graduated from the Philadelphia College of Pharmacy and Science with a Bachelor’s Degree in Pharmacy.

President, India Formulations & MEA (Middle East & Africa) Region

Mr. Sujesh Vasudevan

Mr. Sujesh Vasudevan is Glenmark’s President, India Formulations and the Middle East & Africa (MEA) regions. He has overall charge of the company’s generics and branded pharmaceutical businesses across India, Middle East and Africa. Prior to joining Glenmark in 2013, he served as Director of Sales & Marketing at Abbott India Limited. Mr. Vasudevan has completed the Advanced Management Program from Harvard Business School. He has also received a Master's Degree in Management Studies from K. J. Somaiya Institute of Management Studies & Research and holds a Bachelor’s Degree in Pharmacy from the K.M. Kundnani College of Pharmacy, Mumbai.

President, Global Innovative Product Development Group

Mr. Robert Jackson

Mr. Robert Jackson is President, Global Innovative Product Development Group at Glenmark Pharmaceuticals Ltd. He leads global product development in the innovative and specialty portfolio at Glenmark. Prior to joining Glenmark in 2015, Mr. Jackson amassed more than 30 years of experience in pharmaceutical research and development including leadership roles in global manufacturing, regulatory affairs, technical research and development, quality assurance, quality control and corporate project management, and pre-and-post approval drug development for more than a dozen approved products in a variety of therapeutic areas at companies such as Forest Laboratories, Inc. and Novartis. He received his Master's in Business Administration in Pharmaceutical Studies from Fairleigh Dickinson University, New Jersey and a Bachelor of Science in Biochemistry from Lynchburg College, Virginia.

President and the Global Head of Operations

Mr. Kanish Malik

President and the Global Head of OperationsMr. Kanish Malik

Mr. Kanish Malik is President and the Global Head of Operations at Glenmark Pharmaceuticals Ltd. In his role, he oversees the operations of 17 manufacturing facilities spread across 4 continents that produce branded and generic medicines as well as active pharmaceutical ingredients. He also manages the global supply chain for the organization. Mr. Malik has over 25 years of industry experience in operations, supply chain management and in leading large, sophisticated manufacturing and service-oriented organizations. Prior to joining Glenmark in 2015, Mr. Malik previously worked with PepsiCo & Unilever and has held a wide range of roles in India and throughout the Asia-Pacific Region. He holds a Bachelor's Degree in Chemical Engineering from Punjab University, India.

President, Global Quality

Dr. Darshan Makhey

President, Global QualityDr. Darshan Makhey

Dr. Darshan Makhey is President, Global Quality at Glenmark Pharmaceuticals Ltd. In this role he has the critical responsibility of protecting and enhancing Glenmark’s reputation for high-quality and reliable products across multiple therapy areas. Dr. Makhey has over 20 years of experience in the industry. He has served in a variety of strategic leadership and executive roles, with increasingly senior positions held in quality and compliance. Prior to joining Glenmark in 2012, he was Head of Global Quality at Dr. Reddy's Laboratories Ltd. He received a PhD in Medicinal Chemistry from Rutgers, The State University of New Jersey.

President - Global General Counsel

Mr. Murali Neelakantan

President - Global General CounselMr. Murali Neelakantan

Mr. Murali Neelakantan is the Global General Counsel at Glenmark Pharmaceuticals Ltd.. He leads the Legal and Compliance functions for the organisation globally. Mr. Neelakantan has more than 20 years of international experience in advising companies in a wide variety of sectors from utilities to financial services.

He has held leadership positions at international law firms such as Arnold & Porter and Ashurst LLP, and at leading Indian law firm, Khaitan & Co. He was also the Global General Counsel at Cipla.

Mr. Neelakantan graduated with honours from National Law School of India University and is qualified to practice law in India, England and Wales.

President-Europe and Emerging Markets

Ms. Camilla Harder Hartvig

President-Europe and Emerging MarketsMs. Camilla Harder Hartvig

Ms. Camilla Harder Hartvig is the President of the Europe and Emerging Markets Business at Glenmark Pharmaceuticals Ltd. Ms Hartvig is based in London and oversees the development and execution of strategy across Europe and the emerging markets (South East Asia, Pacific, Russia & CIS and Latin America), thereby driving the growth of the company’s generics and branded pharmaceutical business in the region.

Ms. Hartvig has more than twenty years of commercial experience in the global pharmaceutical industry. Prior to joining Glenmark, she has held global, regional and local business leadership positions in leading pharmaceutical companies such as Allergan (Actavis), Novartis and AstraZeneca.

Ms. Hartvig, a Danish national, holds a Master's Degree in Business Science from the Copenhagen Business School specializing in International Marketing and Management and a Master’s Degree in CEMS MIM from Ecole Des Hautes Etudes Commerciales (HEC), Paris. Her Bachelor’s in Business Science is also from Copenhagen Business School.